| 7.34 0.5 (7.31%) | 03-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.46 | 1-year : | 10.5 |
| Resists | First : | 8.1 | Second : | 8.98 |
| Pivot price | 7.31  |
|||
| Supports | First : | 6.67 | Second : | 5.54 |
| MAs | MA(5) : | 6.96 |
MA(20) : | 7.39 |
| MA(100) : | 8.89 |
MA(250) : | 8.73 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 14.4 |
D(3) : | 9.8 |
| RSI | RSI(14): 46.4 |
|||
| 52-week | High : | 12.6 | Low : | 4.84 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ KYNB ] has closed below upper band by 48.4%. Bollinger Bands are 4.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7 - 7.04 | 7.04 - 7.07 |
| Low: | 6.57 - 6.62 | 6.62 - 6.66 |
| Close: | 6.77 - 6.85 | 6.85 - 6.9 |
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
Mon, 09 Mar 2026
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Tue, 24 Feb 2026
What's Going On With Kyntra Bio Stock Tuesday? - Sahm
Wed, 07 Jan 2026
FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB - Investing.com
Wed, 07 Jan 2026
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - GlobeNewswire
Wed, 07 Jan 2026
Cancer and rare disease drug maker FibroGen takes new name Kyntra Bio - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 3.56e+006 (%) |
| Held by Institutions | 1.6 (%) |
| Shares Short | 115 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.806e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 2 % |
| Operating Margin | 598.8 % |
| Return on Assets (ttm) | -499.1 % |
| Return on Equity (ttm) | -18.5 % |
| Qtrly Rev. Growth | 8.3e+006 % |
| Gross Profit (p.s.) | 833.11 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.26344e+007 |
| Qtrly Earnings Growth | -12.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.63 |
| Dividend | 0 |
| Forward Dividend | 106990 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|